The Motley Fool

Mesoblast shares halted as it asks investors to tip in another $75 million

Mesoblast limited (ASX: MSB) shares are locked in a trading halt today with the regenerative medicine business reportedly seeking to raise another $75 million according to news reports in the Australian Financial Review.

Mesoblast has often been touted as the next blockbuster company on the ASX and has seen its shares swing wildly in value depending on sentiment and the state of its balance sheet. 

As at June 30 2019 it had US$50.4 million cash on hand but posted a quarterly cash operating loss of US$19.08 million with just $1.038 million in ‘royalty receipts’ received over the quarter.

So given its cash burn rate we can see why the company needs to raise more capital by the issue of another 37.5 million shares at $2 a share according to the AFR.

Bank debt is not really an option for a business like Mesoblast as no mainstream bankers will lend to a company with its kind of cash-burning track record and few assets to securitise against.

The biotech is making progress in commercialising a number of its regenerative medicine products, but it’s been slow going.

For example if we wind the clock back 6 years to the quarter ending June 30 2013 it posted an operating cash loss of A$13.5 million on no sales.

In fairness it’s now starting to bring in decent royalty revenues on sales milestones via partnerships with big pharma. For example over the past 12 months it has earned around US$30.7 million in ‘milestone receipts’.

However, the capital raising story is now so familiar that the heavily dilution means dreams of a sky high share price are all but gone. 

After the latest capital raising it will have over 500 million shares on issue to mean it already has a big market cap around $1.1 billion.

Therefore today’s investors have great expectations in buying a $1 billion biotech business that is still burning through huge amounts of shareholder capital on a regular basis. 

Other speculative healthcare businesses to watch include Avita Medical Ltd (ASX: AVH), Paradigm Biopharmaceuticals Ltd (ASX: PAR) and Opthea Limited (ASX: OPT).

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

*Returns as of June 30th

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Related Articles...

Latest posts by Tom Richardson (see all)